Listed pharmas taking steps back in R&D investment
Listed pharmaceutical companies were criticized that they took a step back in R&D investment.
Yakup Shinmoon(www.yakup.com) analyzed KOSPI and KOSDAQ listed pharmaceutical companies’ 2017 3rd quarter business performances, and the analysis showed their average R&D expenses/sales ratio was 7.7%. ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
